AdHER2DC vaccine
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AdHER2DC vaccine, covering 2026-04-09 to 2026-04-09. Get the full timeline:
Most recent: Clinical Trial Update: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer [Phase 1, Phase 2]